{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:47:26Z","timestamp":1786632446170,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Open Project Funded by Hubei Key Laboratory","award":["2024KFZ024"],"award-info":[{"award-number":["2024KFZ024"]}]},{"name":"Hubei Provincial Health Science and Technology General Project","award":["WJ2025M112"],"award-info":[{"award-number":["WJ2025M112"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12595-z","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:58:21Z","timestamp":1786629501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells"],"prefix":"10.1007","volume":"53","author":[{"given":"Yongfa","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"3","key":"12595_CR1","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/ijms25031845","volume":"25","author":"V Tavares","year":"2024","unstructured":"Tavares V, Marques IS, Melo IG, Assis J, Pereira D, Medeiros R (2024) Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci 25(3):1845","journal-title":"Int J Mol Sci"},{"issue":"7","key":"12595_CR2","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/biomedicines13071525","volume":"13","author":"D Papageorgiou","year":"2025","unstructured":"Papageorgiou D, Liouta G, Pliakou E, Zachariou E, Sapantzoglou I, Prokopakis I et al (2025) Management of advanced ovarian cancer: current clinical practice and future perspectives. Biomedicines 13(7):1525","journal-title":"Biomedicines"},{"key":"12595_CR3","doi-asserted-by":"publisher","first-page":"104434","DOI":"10.1016\/j.critrevonc.2024.104434","volume":"201","author":"I Miras","year":"2024","unstructured":"Miras I, Est\u00e9vez-Garc\u00eda P, Mu\u00f1oz-Galv\u00e1n S (2024) Clinical and molecular features of platinum resistance in ovarian cancer. Crit Rev Oncol Hematol 201:104434","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"12595_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3892\/or.2022.8293","volume":"47","author":"L Yang","year":"2022","unstructured":"Yang L, Xie HJ, Li YY, Wang X, Liu XX, Mai J (2022) Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review). Oncol Rep 47(4):82","journal-title":"Oncol Rep"},{"key":"12595_CR5","first-page":"53","volume":"7","author":"A Ponton-Almodovar","year":"2024","unstructured":"Ponton-Almodovar A, Sanderson S, Rattan R, Bernard JJ, Horibata S (2024) Ovarian tumor microenvironment contributes to tumor progression and chemotherapy response. Cancer Drug Resist 7:53","journal-title":"Cancer Drug Resist"},{"key":"12595_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-981-19-0394-6_7","volume":"1372","author":"XC Jiang","year":"2022","unstructured":"Jiang XC, Chiang YP (2022) Sphingomyelin synthase family and phospholipase Cs. Adv Exp Med Biol 1372:77\u201386","journal-title":"Adv Exp Med Biol"},{"issue":"45","key":"12595_CR7","doi-asserted-by":"publisher","first-page":"17505","DOI":"10.1074\/jbc.RA118.002048","volume":"293","author":"Y Hayashi","year":"2018","unstructured":"Hayashi Y, Nemoto-Sasaki Y, Matsumoto N, Hama K, Tanikawa T, Oka S et al (2018) Complex formation of sphingomyelin synthase 1 with glucosylceramide synthase increases sphingomyelin and decreases glucosylceramide levels. J Biol Chem 293(45):17505\u201317522","journal-title":"J Biol Chem"},{"issue":"1","key":"12595_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/sj.emboj.7600034","volume":"23","author":"K Huitema","year":"2004","unstructured":"Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC (2004) Identification of a family of animal sphingomyelin synthases. EMBO J 23(1):33\u201344","journal-title":"EMBO J"},{"key":"12595_CR9","doi-asserted-by":"publisher","first-page":"941643","DOI":"10.3389\/fonc.2022.941643","volume":"12","author":"RZ Li","year":"2022","unstructured":"Li RZ, Wang XR, Wang J, Xie C, Wang XX, Pan HD et al (2022) The key role of sphingolipid metabolism in cancer: new therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance. Front Oncol 12:941643","journal-title":"Front Oncol"},{"issue":"8","key":"12595_CR10","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.3390\/ijms26083716","volume":"26","author":"A Zhakupova","year":"2025","unstructured":"Zhakupova A, Zeinolla A, Kokabi K, Sergazy S, Aljofan M (2025) Drug resistance: the role of sphingolipid metabolism. Int J Mol Sci 26(8):3716","journal-title":"Int J Mol Sci"},{"key":"12595_CR11","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.molmet.2024.101936","volume":"83","author":"N Wajapeyee","year":"2024","unstructured":"Wajapeyee N, Beamon TC, Gupta R (2024) Roles and therapeutic targeting of ceramide metabolism in cancer. Mol Metab 83:101936","journal-title":"Mol Metab"},{"issue":"1","key":"12595_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/cancers11010088","volume":"11","author":"P Fern\u00e1ndez-Garc\u00eda","year":"2019","unstructured":"Fern\u00e1ndez-Garc\u00eda P, Rossell\u00f3 CA, Rodr\u00edguez-Lorca R, Beteta-G\u00f6bel R, Fern\u00e1ndez-D\u00edaz J, Llad\u00f3 V et al (2019) The opposing contribution of SMS1 and SMS2 to glioma progression and their value in the therapeutic response to 2OHOA. Cancers (Basel) 11(1):88","journal-title":"Cancers (Basel)"},{"issue":"5","key":"12595_CR13","first-page":"4412","volume":"13","author":"F Jing","year":"2021","unstructured":"Jing F, Jing C, Dai X, Zhou G, Di S, Bi X et al (2021) Sphingomyelin synthase 2 but not sphingomyelin synthase 1 is upregulated in ovarian cancer and involved in migration, growth and survival via different mechanisms. Am J Transl Res 13(5):4412\u20134421","journal-title":"Am J Transl Res"},{"issue":"1","key":"12595_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","volume":"184","author":"I Vermes","year":"1995","unstructured":"Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein-labelled Annexin V. J Immunol Methods 184(1):39\u201351","journal-title":"J Immunol Methods"},{"issue":"5","key":"12595_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/cells13050459","volume":"13","author":"I Eriksson","year":"2024","unstructured":"Eriksson I, \u00d6llinger K (2024) Lysosomes in cancer-at the crossroad of good and evil. Cells 13(5):459","journal-title":"Cells"},{"key":"12595_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.20517\/cdr.2018.06","volume":"1","author":"KM Kreitzburg","year":"2018","unstructured":"Kreitzburg KM, van Waardenburg RCAM, Yoon KJ (2018) Sphingolipid metabolism and drug resistance in ovarian cancer. Cancer Drug Resist 1:181\u2013197","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"12595_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000528869","volume":"88","author":"J Zou","year":"2023","unstructured":"Zou J, Jian L (2023) Inhibition of ceramide kinase is effective against cisplatin-resistant ovarian cancer cells by regulating ceramide and C1P levels. Gynecol Obstet Invest 88(1):61\u201370","journal-title":"Gynecol Obstet Invest"},{"issue":"2","key":"12595_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00280-020-04199-6","volume":"87","author":"H Lu","year":"2021","unstructured":"Lu H, Zhou L, Zuo H, Le W, Hu J, Zhang T et al (2021) Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma. Cancer Chemother Pharmacol 87(2):217\u2013228","journal-title":"Cancer Chemother Pharmacol"},{"key":"12595_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41419-019-1303-0","volume":"10","author":"K Zheng","year":"2019","unstructured":"Zheng K, Chen Z, Feng H, Chen Y, Zhang C, Yu J et al (2019) Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin. Cell Death Dis 10:157","journal-title":"Cell Death Dis"},{"issue":"1","key":"12595_CR20","first-page":"483","volume":"15","author":"S Luo","year":"2018","unstructured":"Luo S, Pan Z, Liu S, Yuan S, Yan N (2018) Sphingomyelin synthase 2 overexpression promotes cisplatin-induced apoptosis of HepG2 cells. Oncol Lett 15(1):483\u2013488","journal-title":"Oncol Lett"},{"issue":"2","key":"12595_CR21","first-page":"1159","volume":"19","author":"S Liu","year":"2019","unstructured":"Liu S, Hou H, Zhang P, Wu Y, He X, Li H et al (2019) Sphingomyelin synthase 1 regulates the epithelial-to-mesenchymal transition mediated by the TGF-\u03b2\/Smad pathway in MDA-MB-231 cells. Mol Med Rep 19(2):1159\u20131167","journal-title":"Mol Med Rep"},{"issue":"8","key":"12595_CR22","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1096\/fj.201701016R","volume":"32","author":"S Moorthi","year":"2018","unstructured":"Moorthi S, Burns TA, Yu GQ, Luberto C (2018) Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation. FASEB J 32(8):4270\u20134283","journal-title":"FASEB J"},{"key":"12595_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fphar.2019.00443","volume":"10","author":"F Bilal","year":"2019","unstructured":"Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S et al (2019) Sphingomyelin synthase 1 (SMS1) downregulation is associated with sphingolipid reprogramming and a worse prognosis in melanoma. Front Pharmacol 10:443","journal-title":"Front Pharmacol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12595-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12595-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12595-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:58:22Z","timestamp":1786629502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12595-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12595"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12595-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1400"}}